the aid library

LIST OPTIONS

Filter

10262

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (252)

View PDF (185)

My Pregnancy (Arabic Version)

Health Service Excecutive HSE Ireland (2021) CC

Download (434)

View PDF (696)

Education Capacity Self-Assessment: Transforming the Education Humanitarian Response of the Rohingya Refugee Crisis (Cox’s Bazar, Bangladesh, March 2018)

UN Children's Fund, BRAC, Education Cluster, Norwegian Capacity (2018) CC

Download (256)

View PDF (410)

Improving Prison Conditions by Strengthening the Monitoring of HIV, HCV, TB and Harm Reduction (Portugal)

N. H. Ponters, A. P. Dores CIES IUL; ISCTE IUL; European Union (2015) C2

Mapping Report - Portugal

Download (1225)

View PDF (853)

Integration of Expanded Programme on Immunisation and Family Planning Clinics: Value for Money Study

Rachel Phillipson Nepal Health Sector Support Programme (2013)

Download (688)

View PDF (867)

Brief, structured psychological treatment

World Health Organization WHO (2012) C_WHO

Q 3: Is brief, structured psychological treatment in non-specialist health care settings better (more effective than/as safe as) than treatment as usual in people with depressive episode/disorder?

Download (748)

View PDF (1410)

Ghana National Health Policy: Creating Wealth through Health

Ministry of Health Ghana; (2007) C1

Download (590)

View PDF (1010)

Tanzania: HIV Care and Treatment Plan 2003-2008

The William J. Clinton Foundation Ministry of Health, Tanzania (2003) C1

External Link

COVID-19 in Malawi: lessons in pandemic preparedness from a tertiary children’s hospital

Chaziya J, Freyne B, Lissauer S et al. (2021) CC

Archives of Disease in Childhood 2021;106:238-240.

Download (278)

View PDF (643)

Relevance of CBR and Inclusive Development in Post 2015 Agenda

Thomas, M. and Ninomiya, A. CBR Asia-Pacific Network (2015) C1

Download (173)

View PDF (193)

Save the Children's COVID-19 Program Framework and Guidance and Companion Pieces

Save the Children (2020) C1

How we respond both now and going forward will help mitigate the impact of COVID-19, and to the extent possible preserve children’s rights to Survive, Learn, and Be Protected. We will focus our efforts on the most critical work essential to maintaining these commitments to the extent possible.

Download (1527)

View PDF (557)

Child Protection Case Management Training Manual

The Government of Malawi PEPFAR; UNICEF (2017) C1

This five-day child protection case management training manual was developed to meet the needs of community child protection workers and other social workers working in tandem with the justice, health and law enforcement systems in Malawi.

Download (460)

View PDF (644)

Namibia 2011 Census Disability Report

Namibia Statistics Agency (2016) C2

Download (180)

View PDF (178)

Использование методов визуализации органов грудной клетки при COVID-19 : краткое руководство

World Health Organization WHO (2020) C_WHO

В этом Кратком руководстве рассматриваются фактические данные и даются рекомендации по использованию методов визуализации органов грудной клетки при оказании н... more

Download (146)

View PDF (203)

Tracking official development assistance for reproductive health in conflict-affected countries: 2002—2011

Patel P.; Dahab M.; Tanabe M. et al. BJOG An International Journal of Obstetics and Gynaecology (2016) CC

To provide information on trends on official development assistance (ODA) disbursement patterns for reproductive health activities in 18 conflict-affected countries

Download (257)

View PDF (458)

Break Through - November 2012

Cerebral Palsy Alliance Research Foundation (2012) C2

THE RESEARCH FOUNDATION OF CEREBRAL PALSY ALLIANCE newsletter – NOVEMBER 2012

Download (591)

View PDF (396)

Perceived Susceptibility of Persons with Physical Disability to Factors Contributing to the Risk of Contracting HIV in Cameroon: A Qualitative Study

Elvis E. Tarkang, Prosper M. Lutala International Journal of HIVAIDS Prevention, Educa tion and Behavioural Science (2015) CC

Download (1590)

View PDF (2052)

Measles SIAs Field Guide

World Health Organization; Regional Office for Africa (2006)

The Regional strategy for measles control recommends that a second opportunity for measles immunization be provided to all children irrespective of their vaccination status or history of clinical measles. The preferred method of provision of a second opportunity is through Supplemental Immunization ... more

Download (1471)

View PDF (1303)

Nutrition Curriculum: Basic and Advanced Modules Training Manual

The Border Consortium (TBC), International Rescue Committee (2017) C1

The Border Consortium (TBC) developed a comprehensive Training of Trainers Nutrition Curriculum which includes 12 Modules (6 Basic and 6 Advanced topics). The Manual provides trainers with standardized methods and content to deliver nutrition training.
Original file: 25 MB

Download (2090)

View PDF (2680)

Global Disease Detection (GDD) Manual “Rapid Diagnostic Tests for Epidemic Diseases”

Center for Disease Control Centers for Disease Control and Prevention (CDC) (2011) C_CDC